CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.113
https://www.valueinhealthjournal.com/article/S1098-3015(23)00213-9/fulltext
Section Title :
Section Order :
10576
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00213-9&doi=10.1016/j.jval.2023.03.113